Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2011-08-16
2011-08-16
Lewis, Patrick (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S025000, C514S033000, C514S035000, C514S054000
Reexamination Certificate
active
07998943
ABSTRACT:
A method of treating a subject in need of therapy for a condition involving detrimental activity of the enzyme core 2 GlcNAc-T is provided, comprising administration of a therapeutically effective amount of an inhibitor of core 2 GlcNAc-T of the formula I to a patient in need thereofwhereinR1is H, —OH, C1-6alkoxy, —NR5R6, or Sac 1;R2is H, —OH, C1-6alkoxy or Sac 2;R3is H, —OH, C1-6alkoxy or Sac 3;R4is H, C1-6alkyl, C1-6hydroxyalkyl or C1-6-alkoxy-C1-6-alkyl;R5is H, C1-6alkyl or C1-6acyl;R6is H, C1-6alkyl or C1-6acyl;Sac 1 Sac 2 and Sac 3 are independently selected saccharide moieties, andZ is a steroid moiety;or a pharmaceutically acceptable salt, ether or ester form thereof.
REFERENCES:
patent: 4602003 (1986-07-01), Malinow
patent: 5104856 (1992-04-01), Esko et al.
patent: 5360733 (1994-11-01), Fukuda et al.
patent: 5461143 (1995-10-01), Wong et al.
patent: 5470879 (1995-11-01), Sauvaire et al.
patent: 5486510 (1996-01-01), Bouic et al.
patent: 5589182 (1996-12-01), Tashiro et al.
patent: 5624832 (1997-04-01), Fukuda et al.
patent: 5658778 (1997-08-01), Fukuda et al.
patent: 5684134 (1997-11-01), Fukuda et al.
patent: 5827884 (1998-10-01), Obagi
patent: 5843707 (1998-12-01), Larsen et al.
patent: 5880091 (1999-03-01), Cummings et al.
patent: 5886029 (1999-03-01), Dhaliwal
patent: 5952393 (1999-09-01), Sorkin, Jr.
patent: 5958770 (1999-09-01), Cham et al.
patent: 5965449 (1999-10-01), Novak
patent: 5985936 (1999-11-01), Novak
patent: 5997877 (1999-12-01), Chang
patent: 6042834 (2000-03-01), Baraka
patent: 6087353 (2000-07-01), Stewart et al.
patent: 6131578 (2000-10-01), King et al.
patent: 6197832 (2001-03-01), Sorkin, Jr.
patent: 6294157 (2001-09-01), Rubinstenn et al.
patent: 6346267 (2002-02-01), Fry et al.
patent: 6383514 (2002-05-01), Weitkemper et al.
patent: 6407085 (2002-06-01), Kief
patent: 6451355 (2002-09-01), Reisner
patent: 6593301 (2003-07-01), Ma et al.
patent: 6635461 (2003-10-01), Schwientek et al.
patent: 6787151 (2004-09-01), Meijer et al.
patent: 6933291 (2005-08-01), Qi et al.
patent: 6998501 (2006-02-01), Wright et al.
patent: 2002/0016314 (2002-02-01), Schersi
patent: 2002/0018811 (2002-02-01), Penteado et al.
patent: 2002/0098563 (2002-07-01), Korczak et al.
patent: 2002/0107292 (2002-08-01), Bortlik et al.
patent: 2002/0156051 (2002-10-01), Kutney et al.
patent: 2002/0183294 (2002-12-01), Barraclough et al.
patent: 2002/0193317 (2002-12-01), Xia et al.
patent: 2003/0004147 (2003-01-01), Barraclough et al.
patent: 2003/0096316 (2003-05-01), Wester
patent: 2003/0148962 (2003-08-01), Guan et al.
patent: 2004/0033521 (2004-02-01), Korczak et al.
patent: 2004/0038923 (2004-02-01), Marth et al.
patent: 2004/0049352 (2004-03-01), Andre et al.
patent: 2004/0203111 (2004-10-01), Schwientek et al.
patent: 2004/0220115 (2004-11-01), Cham
patent: 2004/0249138 (2004-12-01), Lawson
patent: 2006/0052351 (2006-03-01), Platt et al.
patent: 2007/0254847 (2007-11-01), Liu et al.
patent: 2008/0318875 (2008-12-01), Chibber
patent: 2 186987 (1998-04-01), None
patent: 2 335 436 (2001-08-01), None
patent: 1 237 583 (1999-12-01), None
patent: 1237583 (1999-12-01), None
patent: 1243129 (2000-02-01), None
patent: 1361111 (2000-12-01), None
patent: 1361111 (2002-07-01), None
patent: 1 397 545 (2003-02-01), None
patent: 1 511 535 (2004-07-01), None
patent: 1 562 064 (2005-01-01), None
patent: 4303214 (1994-11-01), None
patent: 0 251 197 (1988-01-01), None
patent: 0 251 197 (1988-01-01), None
patent: 1 316 608 (2003-06-01), None
patent: 0 850 243 (2003-10-01), None
patent: 1 800 685 (2007-06-01), None
patent: 03271224 (1991-03-01), None
patent: 2004-143126 (2004-05-01), None
patent: 2 027 434 (1995-01-01), None
patent: 2027434 (1995-01-01), None
patent: 833254 (1981-05-01), None
patent: WO 95/17182 (1995-06-01), None
patent: WO 95/21199 (1995-08-01), None
patent: WO 95/35294 (1995-12-01), None
patent: WO 97/06176 (1997-02-01), None
patent: WO 97/47298 (1997-12-01), None
patent: WO 98/06405 (1998-02-01), None
patent: 98/14459 (1998-04-01), None
patent: WO 98/33494 (1998-08-01), None
patent: WO 98/33494 (1998-08-01), None
patent: WO 99/25197 (1999-05-01), None
patent: WO 99/25197 (1999-05-01), None
patent: WO 99/39715 (1999-08-01), None
patent: WO 99/53925 (1999-10-01), None
patent: WO 00/31109 (2000-06-01), None
patent: WO 00/31109 (2000-06-01), None
patent: WO 00/52029 (2000-09-01), None
patent: WO 00/61153 (2000-10-01), None
patent: WO 00/78789 (2000-12-01), None
patent: WO 01/32679 (2001-05-01), None
patent: 01/58932 (2001-08-01), None
patent: WO 01/83717 (2001-11-01), None
patent: WO 01/87548 (2001-11-01), None
patent: WO 02/03996 (2002-01-01), None
patent: WO 02/24212 (2002-03-01), None
patent: WO 02/069980 (2002-09-01), None
patent: WO 02/087548 (2002-11-01), None
patent: 03/043433 (2003-05-01), None
patent: 03/066679 (2003-08-01), None
patent: WO 03/070261 (2003-08-01), None
patent: WO 03/075931 (2003-09-01), None
patent: 03/092394 (2003-11-01), None
patent: WO 2004/002497 (2004-01-01), None
patent: WO 2004/019960 (2004-03-01), None
patent: WO 2004/029068 (2004-04-01), None
patent: WO 2004/048938 (2004-06-01), None
patent: WO 2004/062675 (2004-07-01), None
patent: WO 2004/064852 (2004-08-01), None
patent: 2004/074461 (2004-09-01), None
patent: WO 2004/093662 (2004-11-01), None
patent: WO 2004/111196 (2004-12-01), None
patent: WO 2005/060977 (2005-07-01), None
patent: WO 2005/084323 (2005-09-01), None
patent: WO 2005/120535 (2005-12-01), None
patent: 2006/034655 (2006-04-01), None
patent: WO 2006/034655 (2006-04-01), None
patent: WO 2006/034655 (2006-06-01), None
patent: 00135190.7 (2005-01-01), None
Mimaki et al. Phytochemistry (1996), vol. 42, pp. 1065-1070.
Co-Pending U.S. Appl. No. 11/472,554, filed Jun. 22, 2006.
Co-Pending U.S. Appl. No. 10/584,470, filed Jun. 22, 2006.
Co-Pending U.S. Appl. No. 11/481,255, filed Jul. 6, 2006.
Chibber, R., et al; “Activity of the Glycosylating Enzyme, Core 2 GlcNAc (β1,6) Transferase, is Higher in Polymorphonuclear Leukocytes From Diabetic Patients Compared With Age-Matched Control Subjects”;Diabetes; vol. 49; pp. 1724-1730 (2000).
Chibber, R., et al; “Protein Kinase C β2-Dependent Phosphorylation of Core 2 GlcNAc-T Promotes Leukocyte-Endothelial Cell Adhesion”;Diabeties; vol. 52; pp. 1519-1527 (2003).
Ellies, L.G., et al; “Core 2 Oligosaccharide Biosynthesis Distingjishes between Selectin Ligands Essential for Leukocyte Homing and Inflammation”;Immunity; vol. 9, pp. 881-890 (1998).
Goekjian, P.G., et al; “Protein kinase C inhibitors as novel anticancer drugs”;Expert Opin. Investig. Drugs; vol. 10, No. 12; pp. 2117-2140 (2001).
Hartung, Hans-Peter, MD; et al; “Circulating Adhesion Molecules and Tumor Necrosis Factor Receptor in Multiple Sclerosis: Correlation with Magnetic Resonance Imaging”;Annals of Neurology; vol. 38, No. 2; pp. 186-193 (1995).
Hindsgaul, O., et al; “Evaluation of Deoxygenated Oligosaccharide Acceptor Analogs as Specific Inhibitors of Glycosyltransferases”;The Journal of Biological Chemistry; vol. 266, No. 27; pp. 17858-17862 (1991).
Joshi, J., et al; “Chemistry of Ayurvedic Crude Drugs: Part VIIIa-Shatavari-2: Structure Elucidation of Bioactive Shatavarin-I & other Glycosidesb,c”;Indian Journal of Chemistry; vol. 27B; pp. 12-16 (1988).
Kim, S.Y., et al; “Inhibition of Mouse Ear Edema by Steroidal and Triterpenoid Saponins”;Arch Pharm Res.; vol. 22, No. 3, pp. 313-316 (1999).
Kuhns, W., et al; “ProcessingO-glycan core 1, Galβ1-3GaINAcα-R. Specificities of core 2, UDP-GlcNAc: Galβ1-3GalNAc-R(GlcNAc to GalNAc)β6-N-acetylglucosaminyltransferase and CMP-sialic acid: Galβ1-3GaINAc-R α3-sialyltransferase”;Glycoconjugate Journal; vol. 10; pp. 381-394 (1993).
Matsuda, H., et al; “Protective Effects of Steroid Saponins fromParis polyphyllavar.yunnanensison Ethanol- or Indomethacin-Induced Gastric Mucosal Lesions in Rats: Structural Requirement for Activity and Mode of Action”;Bioorganic&Medicinal Chemist
Chibber Rakesh
Hagan Russell
BTG International Limited
Lewis Patrick
Nixon & Vanderhye
LandOfFree
Core 2 GlcNAc-T inhibitors III does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Core 2 GlcNAc-T inhibitors III, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Core 2 GlcNAc-T inhibitors III will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2738832